根据 位华尔街分析师的预测,ProUroCare Medical Inc 的收入预期范围从 $ 到 $
ProUroCare Medical Inc 的盈利质量评分是多少?
ProUroCare Medical Inc 的盈利质量评分为 B+/44.948986。该评分基于盈利能力、增长、现金生成与资本分配以及杠杆四个维度。
ProUroCare Medical Inc 何时发布财报?
ProUroCare Medical Inc 的下一份财报预计在 发布
ProUroCare Medical Inc 的预期收益是多少?
根据华尔街分析师的预测,ProUroCare Medical Inc 的预期收益为 $
ProUroCare Medical Inc 是否超出收益预期?
ProUroCare Medical Inc 最近的收益为 $, 预期。
关键数据
前收盘价
$0.0001
开盘价
$0.0002
当日区间
$0.0001 - $0.0002
52周范围
$0.0001 - $0.0002
交易量
26.1K
平均成交量
1.5K
股息收益率
--
每股收益(TTM)
-0.14
市值
$1.8K
什么是 PUMD?
ProUroCare Medical, Inc. engages in the development of products for the detection and characterization of male prostate disease. The company is headquartered in Eden Prairie, Minnesota and currently employs 2 full-time employees. The company went IPO on 2002-05-28. The firm is focused on its product, a prostate mechanical imaging device called the ProUroScan System. The ProUroScan is an advanced medical imaging system that uses an array of sensors mounted on a rectal probe, a central processing unit and software and image construction algorithms to provide a real time color image of abnormalities in the prostate. The ProUroScan System probe is specially designed for the rectal anatomy to minimize patient discomfort. In addition, it provides mechanical or elasticity imaging, which refers to a non-invasive analysis of tissue movement and displacement. The ProUroScan technique works by computing how tissue moves in response to pressure, thus evaluating its softness or stiffness. Its product also provides two-and three-dimensional prostate images.